Skribe Medical, Inc.

Skribe Medical, Inc. focuses on developing innovative battery-free, multi-sensor patches for cardiac monitoring, specifically designed to assist cancer patients by continuously measuring vital health signals, thereby improving patient care. Founded in 2024 in Mill Valley, US, Skribe Medical, Inc. specializes in cardiac monitoring solutions for cancer patients.

The company launched with a vision to enhance patient monitoring and safety during cancer treatments and has since secured its first deal. The latest funding round occurred in September 2025, with the company raising an undisclosed amount in pre-seed financing led by Marin Sonoma Impact Ventures, alongside participation from GoAhead Ventures and individual investors. The founder's history is not explicitly detailed in the provided information. Skribe Medical’s core product offering revolves around innovative battery-free, multi-sensor patches designed for cardiac monitoring in cancer patients.

These patches enable continuous measurement of vital health signals, allowing for early intervention to mitigate heart damage risks associated with cancer therapies. The technology encompasses the entire process, from hardware setup and data collection to generating curated reports essential for healthcare providers. Skribe Medical's solutions target healthcare institutions and oncologists primarily in North America and Europe, addressing the need for improved patient monitoring during cancer treatments. Skribe Medical generates revenue through the direct sales of its multi-sensor patches along with associated services like installation and data analytics.

The company operates on a business-to-business (B2B) model, partnering with hospitals and healthcare providers who use the patches in their oncology departments. Their revenue model may include subscription-based access to data analytics and reporting services, enabling continuous patient health monitoring and actionable insights. Pricing structures for patches and services are customized for institutional contracts, demonstrating the value of enhanced patient monitoring capabilities. Skribe Medical plans to utilize the funding from the September 2025 pre-seed round to advance its wireless wearable patch technology.

The company is focused on developing new products and expanding into new geographic markets. Specific regions targeted for expansion have not been detailed, but the company aims to broaden its reach in North America and Europe. The recent funding will support these initiatives, emphasizing the enhancement of patient care and monitoring capabilities through innovative technology.